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The death of adolescent and young adult patients due to
sarcoma is a tragedy. In efforts to avoid this, much
development of treatment strategies has occurred in the
past several years. These include not only technical
developments such as molecular targeted therapy, heavy
particle radiotherapy, Intensity Modulated Radiation
Therapy (IMRT), Tomotherapy, PET-CT, and interven-
tional radiology, but also improvements in the medical
systems such as standardization of chemotherapy by the
Japan Clinical Oncology Group (JCOG), establishment of
the Japanese Society of Medical Oncology, home health
care program, rehabilitation for cancer patients, and cancer
board. Intense discussion on these new and multimodal
approaches is being anticipated at the 47th Annual Mus-
culoskeletal Tumor Meeting of the Japanese Orthopaedic
Association (JOA), which will be held July 17–18, 2014 in
Osaka, Japan [1]. In preparation for the meeting, several
topics are outlined below.
Since the discovery of the double helix structure of
DNA, researchers have intently studied the causes of can-
cer development. Chromosomal translocations, oncogenes,
and anti-oncogenes were the main themes in cancer
research during the 1960s and through the 1990s. In the
orthopaedic field, mainly retinoblastoma genes in osteo-
sarcoma and fusion genes in soft tissue sarcomas were
investigated [2]. As molecular biology techniques have
progressed, the driver mutation of several cancers revealed
abnormalities in tyrosine kinases that work in the signal
transduction of cancer cells. Subsequently, inhibitors of the
abnormal tyrosine kinases were generated and marketed for
medical use, such as imatinib for chronic myelogenous
leukemia (CML) and gefitinib for epidermal growth factor
receptor (EGFR) mutation-positive lung cancer. These
drugs have dramatically changed the prognosis of the
patients.
For sarcoma, pazopanib, a multi-targeted tyrosine kinase
inhibitor, was marketed for medical use approximately
one year ago in Japan. The phase III clinical trial in 72
institutions across 13 countries revealed a median pro-
gression-free survival of 4.6 months (95 % CI 3.7–4.8) for
pazopanib, compared with 1.6 months (0.9–1.8) for pla-
cebo [hazard ratio (HR) 0.31, 95 % CI 0.24–0.40;
p \ 0.0001] [3]. Even with only one year’s experience of
clinical use, there exists a population of super-responders
to pazopanib, as observed with gefitinib. Although careful
attention to the occurrence of pneumothorax is necessary
due to the complete remission of lung metastases in the
super-responders, this drug is considered a breakthrough in
sarcoma treatment. Further investigations on the driver
pathway in individual histology of sarcoma and its syner-
getic effects with other drugs are expected as issues for
future study.
A 30-year history of prosthetic reconstruction of
malignant bone tumor has revealed the increasing impor-
tance of maintenance surgery for the prosthesis. The design
of knee joint mechanisms is changing from a rigid con-
strained type to a rotating hinge type. However, infection,
breakage, and hinge replacement are still the major prob-
lems in prosthetic surgery. Orthopaedic oncologic surgeons
should be encouraged to generate creative ideas to reduce
the need for maintenance surgery.
Instead of the prosthesis, recycled bone may be a good
substitute for certain cases. Irradiation, pasteurization, heat
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treatment, and freezing are used to kill the tumor cells in
the autogenous graft of tumor-bearing bone. From the long-
term results of our cases of irradiated bone graft, it is
important to use recycled bone graft with the awareness of
the advantages and disadvantages of the methods. The
disadvantages include high rates of complication and re-
operation of osteoarticular grafts. The advantages include
the preservation of tendon and muscle insertion for better
function. We should be aware of the features and should
apply this method to qualifying patients with appropriate
indications [4, 5].
Instead of surgery, heavy particle radiotherapy has
become the first choice of treatment for large sacral
chordoma. Other inoperable sarcomas of the pelvis or spine
are also being treated by this method. The high biological
effectiveness and Bragg peak present a chance to survive
for patients with desperate conditions. However, the bone
destruction after this radiation is extremely severe; there-
fore orthopaedic surgeons need to establish a salvage
method for post-radiation deformity of the spine or pelvis.
Other stereotactic body radiation therapies, such as Novalis
and Tomotherapy, are also useful treatment choices for
selected patients. In addition to these available techniques,
Boron Neutron Capture Therapy (BNCT) is now under
investigation as the next generation radiotherapy. It utilizes
the difference in 10B-concentration between the tumor and
normal tissue under irradiation with thermal neutrons. Soft
tissue sarcomas are reported as promising targets for future
BNCT research. In addition to these improvements in
irradiation techniques, interventional radiology, such as
trans-catheter arterial embolization (TAE) using permanent
embolic material, radiofrequency ablation (RFA), and
kyphoplasty are also undergoing developments. Applica-
tion of these new techniques in radiology will be expected
to give new clinical benefits to the patients.
Despite the improvement of the above-mentioned
treatment strategies, pathological fractures and paraplegia
from spinal metastasis remain as major problems. There are
neither standardized guidelines nor clinical trials to aid in
the decision of treatment procedure for these conditions.
Moreover, since most orthopaedic surgeons are not familiar
with malignant diseases because of the rarity of malig-
nancy in the bone and soft tissues, it is very difficult to
select the appropriate operative procedure for these con-
ditions. Apparently, more studies in this field are urgently
required. Aside from surgical intervention, PET-CT, and
bone modifying agent (BMA), molecular targeted drugs for
cancer have appeared with remarkable influence and
impact on the treatment strategy of bone metastasis. PET-
CT can easily detect the tumor spread. BMA, such as
zoledronic acid and denosumab, decreases the skeletal
related event. The super-responders to molecular targeted
therapy have changed our concepts on treatment of bone
metastasis in that they usually do not need operation. In
addition, a promising procedure, MRI-guided focused
ultrasound (FUS), has received food and drug administra-
tion approval for pain relief of bone metastasis in the
United States. Now is the time for orthopaedic oncologists
to play a part in the establishment of practical guidelines,
medical care systems, and new clinical trials for bone
metastasis.
Enthusiasm for the cooperation of molecular biology,
pharmacology, surgery, radiology, and medical systems
will be the key for better prognosis of patients in the field
of orthopaedic oncology. Hopefully, attendees of the
upcoming 47th Annual Musculoskeletal Tumor Meeting of
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